Journal of Clinical & Experimental Nephrology

Overexpression and Prognostic Significance of PTPN2 May be a Novel Immunotherapy Target in Renal Clear Cell Carcinoma

Immunotherapy has significantly advanced in Clear Cell Renal Cell Carcinoma (ccRCC). We aimed to find a new immune-related prognostic biomarker and immunotherapeutic target for ccRCC. We analyzed the expression, survival, and related immune gene marker sets data of PTPN2 in patients with ccRCC from TCGA. PTPN2 expression was increased in ccRCC compared to normal tissue. PTPN2 was closely related to T stage (P=0.008), TNM stage (P=0.017) and Grade (P=0.002). Overexpression of PTPN2 predicted a poor survival in ccRCC (P< 0.001). PTPN2 was also related to six types of tumor immune-infiltrating cells, including B cells, CD8+T cells, CD4+T cells, Macrophage, Neutrophils, Dendritic cells. PTPN2 was related CTLA-4 (P=5.645404E-26, r=0.4339333) and PDCD1 (P=5.645404E-26, r=0.4339333). Furthermore, the survival rate in patients with high PTPN2 and CTLA4 was significantly lower than that other three strata (P<0.0001). GSEA and GO biological analysis was conducted, which was indicated PTPN2 was involved in many immune and inflammatory pathways, including IL-4, IL-12, CD3 T-cell, CD4 T-cell, intestinal inflammation, systemic inflammatory regulation related factors, and so on. Our results implied that PTPN2 was considered as the potential immune therapeutic target and prognostic biomarker in ccRCC.

Author(s): Peipei Liu

Abstract | Full-Text | PDF

Share this